This antiviral feature of SCYL2, and its dysfunction in our patient, may have played a role in the recurrent upper respiratory tract infections observed, although infections were not reported in any of the other patients with SCYL2 mutations [11,12]. The gene discussed is SCYL2; the disease is Recurrent upper respiratory tract infections.